Interim report 1 January - 30 June 1999

Interim report 1 January - 30 June 1999 @ Medivir buys back MIV-606 shingles drug @ Phase II studies of ME-609 herpes cream have started @ HIV drug MIV-150 approved for clinical phase I trials @ Profit after financial items of 28.5 MSEK (-15.0 MSEK) ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/08/18/19990818BIT00120/bit0001.doc The full report http://www.bit.se/bitonline/1999/08/18/19990818BIT00120/bit0002.pdf The full report

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Subscribe